Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary

  Ovarian Neoplasms

  Free Subscription


16.12.2019

1 BMC Cancer
1 Clin Cancer Res
2 Curr Opin Obstet Gynecol
3 Gynecol Oncol
1 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. HAN GH, Chay DB, Nam S, Cho H, et al
    Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer.
    BMC Cancer. 2019;19:1202.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  2. OZA AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, et al
    A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer.
    Clin Cancer Res. 2019 Dec 12. pii: 1078-0432.CCR-19-1638.
    PubMed     Text format     Abstract available


    Curr Opin Obstet Gynecol

  3. WALSH CS
    Latest clinical evidence of maintenance therapy in ovarian cancer.
    Curr Opin Obstet Gynecol. 2019 Dec 10. doi: 10.1097/GCO.0000000000000592.
    PubMed     Text format     Abstract available

  4. KUBALANZA K, Konecny GE
    Mechanisms of PARP inhibitor resistance in ovarian cancer.
    Curr Opin Obstet Gynecol. 2019 Dec 6. doi: 10.1097/GCO.0000000000000600.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  5. VERGOTE I, Bergfeldt K, Franquet A, Lisyanskaya AS, et al
    A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel.
    Gynecol Oncol. 2019 Dec 9. pii: S0090-8258(19)31685.
    PubMed     Text format     Abstract available

  6. GITTO SB, Kim H, Rafail S, Omran DK, et al
    An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
    Gynecol Oncol. 2019 Dec 6. pii: S0090-8258(19)31568.
    PubMed     Text format     Abstract available

  7. HINCHCLIFF E, Jazaeri AA
    Sunset, or dawn of a new age for ovarian cancer vaccine therapy?
    Gynecol Oncol. 2019;155:387-388.
    PubMed     Text format    


    PLoS One

  8. WAMBECKE A, Laurent-Issartel C, Leroy-Dudal J, Giffard F, et al
    Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells.
    PLoS One. 2019;14:e0225860.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: